CD22 and gastric cancer: Over the past decade, 15 ADC medications have been successfully brought to market, and more than 100 ADC medications are in different stages of clinical trials.[28, 29] However, the targets of ADC medications are currently limited, and include HER2, CD22, and CD20, generally used to treat breast, lung, and gastric cancer.